We aimed to investigate the oncogenic function and therapeutic significance of the m6A binding protein, YTH domain family 2 (YTHDF2), in ICC progression and cisplatin‐based chemotherapy. This evidence concerns the gene YTHDF2 and intrahepatic cholangiocarcinoma.